uniQure NV (LTS:0EE0) Moat Score: 5/10 (As of Jul. 09, 2026)


LTS:0EE0 uniQure NV LTS:0EE0
47 GF Score
Price $42.90
GF Value $5.79
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is uniQure NV Moat Score?

uniQure NV LTS:0EE0 +4.24% 47 Moat Score is 5 as of Jul. 09, 2026. GuruFocus rates LTS:0EE0 with a GF Score™ of 47/100 and a GF Value™ of $5.79 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,394 Biotechnology companies, uniQure NV ranks better than 96.7% on this metric.

uniQure NV has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

uniQure NV has Narrow Moat: uniQure NV has a solid narrow moat due to its valuable intellectual property in gene therapy and strong R&D capabilities. While it has a competitive edge in its niche, it lacks the broad market leadership and network effects needed for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes uniQure NV might have Narrow Moat - Solid narrow moat.

uniQure NV  (LTS:0EE0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

uniQure NV Moat Score Related Terms

LTS:0EE0 vs ALMS, ARQT, DYN: Moat Score Comparison

For the Biotechnology subindustry, uniQure NV's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

uniQure NV Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, uniQure NV's Moat Score distribution charts can be found below:

* The bar in red indicates where uniQure NV's Moat Score falls into.


LTS:0EE0
47GF Score
uniQure NV LTS:0EE0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
uniQure NV (LTS:0EE0) has a Moat Score of 5 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, uniQure NV ranks #46 out of 1394 companies in the Biotechnology industry, placing it in the top 3.3%.
Is uniQure NV's Moat Score too high?
uniQure NV's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. uniQure NV's value of 5 is 150% above this industry median. Based on the distribution chart, uniQure NV ranks #46 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, uniQure NV has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's Moat Score compare to ALMS and ARQT?
According to the Biotechnology industry distribution chart, uniQure NV ranks #46 out of 1394 companies for Moat Score. This places uniQure NV in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. uniQure NV's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. uniQure NV's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. uniQure NV's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (LTS:0EE0) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.79, compared to a current price of $42.90 — trading 640.9% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. uniQure NV's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For uniQure NV (LTS:0EE0), the current Moat Score is 5 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is uniQure NV (LTS:0EE0) Overvalued in 2026?

Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued. The current stock price of $42.90 is trading 640.9% above its estimated GF Value™ of $5.79. GuruFocus considers uniQure NV to be Significantly Overvalued.

Key valuation signals for LTS:0EE0:

  • Moat Score: 5
  • GF Value™: $5.79 vs. price of $42.90 (640.9% above fair value)
  • GF Score™: 47/100 with 5 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1394)

No single metric tells the full story. See the LTS:0EE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

uniQure NV Business Description

Address Paasheuvelweg 25, Amsterdam, NH, NLD, 1105 BP
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
47GF Score

Get the complete analysis for LTS:0EE0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.90
Price
$5.79
GF Value